Bayer’s Financial Crisis: €3.6 Billion Net Loss in 2025 Amid "Roundup" Litigation Storm

The German pharmaceutical and life sciences giant Bayer reported a staggering net loss of €3.6 billion ($4.2 billion) for the fiscal year 2025, primarily weighed down by the massive legal costs associated with its glyphosate-based herbicide, Roundup. Despite being a global leader in seeds and crop protection, the Leverkusen-based company saw its sales dip by 2.2% to €45.6 billion. The financial strain follows a landmark $7.25 billion settlement reached in February to resolve class-action lawsuits in the United States, marking a painful chapter in the company's efforts to move past the litigation era inherited from its Monsanto acquisition.

Looking ahead, Bayer’s management is projecting a period of stabilization for 2026, with sales expected to hold steady between €45 billion and €47 billion. However, the path to recovery has come at a human cost, as the company reduced its workforce by 5,000 employees over the past year, starting 2026 with a total headcount of 88,000. While the projected operating profit of €9.6 to €10.1 billion for the coming year signals a halt to the freefall, Bayer remains under intense scrutiny from investors as it navigates the complex intersection of chemical innovation and environmental liability on the global stage.